
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Post-Marketing Surveillance</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header><h1>Post-Marketing Surveillance</h1></header>
  <nav><a href="index.html">Back to Home</a></nav>
  <main>


 <section>
      <h2>What is Post-Marketing Surveillance?</h2>
      <p>Post-marketing surveillance (PMS) refers to the monitoring of pharmaceutical products after they have been released to the market. It ensures continued safety, efficacy, and quality of drugs in real-world settings and helps identify rare or long-term adverse effects.</p>
    </section>

    <section>
      <h2>Basic Concepts</h2>
      <ul>
        <li><strong>Pharmacovigilance:</strong> The science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems.</li>
        <li><strong>Adverse Drug Reaction (ADR):</strong> Any unintended and harmful reaction to a drug.</li>
        <li><strong>Risk Management:</strong> Strategies to minimize risks associated with drug use.</li>
      </ul>
    </section>

    <section>
      <h2>Safety Monitoring</h2>
      <ul>
        <li>Spontaneous reporting systems (e.g., FDA MedWatch, EudraVigilance)</li>
        <li>Active surveillance programs</li>
        <li>Prescription event monitoring</li>
        <li>Patient registries and cohort studies</li>
        <li>Signal detection and risk evaluation</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Evidence (RWE)</h2>
      <ul>
        <li>Data collected from electronic health records (EHR), insurance claims, and patient-reported outcomes</li>
        <li>Used to assess effectiveness, safety, and utilization patterns</li>
        <li>Supports regulatory decisions and label updates</li>
      </ul>
    </section>

    <section>
      <h2>Technologies and Tools</h2>
      <ul>
        <li>Pharmacovigilance databases (e.g., VigiBase, FAERS)</li>
        <li>Natural language processing for adverse event extraction</li>
        <li>AI and machine learning for signal detection</li>
        <li>Mobile apps for patient reporting</li>
        <li>Blockchain for secure data sharing</li>
      </ul>
    </section>

    <section>
      <h2>Challenges in Post-Marketing Surveillance</h2>
      <ul>
        <li>Underreporting and data quality issues</li>
        <li>Difficulty in establishing causality</li>
        <li>Privacy and data protection concerns</li>
        <li>Global harmonization of surveillance practices</li>
        <li>Timely signal detection and response</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Examples</h2>
      <ul>
        <li><strong>Rofecoxib (Vioxx):</strong> Withdrawn due to increased cardiovascular risk identified post-marketing.</li>
        <li><strong>Thalidomide:</strong> Historical example that led to stricter PMS regulations.</li>
        <li><strong>COVID-19 vaccines:</strong> Ongoing global surveillance for rare adverse events.</li>
      </ul>
    </section>

    <section>
      <h2>Future Directions</h2>
      <ul>
        <li>Global pharmacovigilance networks and data sharing</li>
        <li>Integration of wearable devices and digital biomarkers</li>
        <li>Real-time surveillance using big data analytics</li>
        <li>Patient-centric reporting and engagement</li>
        <li>Regulatory use of RWE for label expansion and safety updates</li>
      </ul>
    </section>
 

    
    
  </main>
  <footer><p>&copy; 2025 Drug Discovery Knowledge Base</p></footer>
</body>
</html>
